[1] |
Hsieh RW, Ravindran A, Hook CC, et al. Etiologies of extreme thrombocytosis: a contemporary series[J]. Mayo Clin Proc, 2019, 94(8):1542-1550.
doi: S0025-6196(19)30211-3
pmid: 31378229
|
[2] |
肖志坚. 原发性血小板增多症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(10):833-836.
|
[3] |
Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside[J]. Br J Haematol, 2013, 161(6):778-793.
doi: 10.1111/bjh.2013.161.issue-6
URL
|
[4] |
Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response[J]. Biochem J, 1990, 265(3):621-636.
doi: 10.1042/bj2650621
URL
|
[5] |
Unsal E, Aksaray S, Koksal D, et al. Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis[J]. Postgrad Med J, 2005, 81(959):604-607.
doi: 10.1136/pgmj.2004.030544
URL
|
[6] |
Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia[J]. Blood, 1995, 85(11):3066-3076.
doi: 10.1182/blood.V85.11.3066.bloodjournal85113066
URL
|
[7] |
Ceresa IF, Noris P, Ambaglio C, et al. Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders[J]. Platelets, 2007, 18(8):579-582.
pmid: 18041648
|
[8] |
Eulenfeld R, Dittrich A, Khouri C, et al. Interleukin-6 signalling: more than Jaks and STATs[J]. Eur J Cell Biol, 2012, 91(6-7):486-495.
doi: 10.1016/j.ejcb.2011.09.010
pmid: 22138086
|
[9] |
Dalton RR, Hoffman WH, Passmore GG, et al. Plasma C-reactive protein levels in severe diabetic ketoacidosis[J]. Ann Clin Lab Sci, 2003, 33(4):435-442.
pmid: 14584758
|
[10] |
Li J, Huang M, Shen X. The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis[J]. J Diabetes Complications, 2014, 28(5):662-666.
doi: 10.1016/j.jdiacomp.2014.06.008
URL
|
[11] |
Ivaska L, Elenius V, Mononen I, et al. Discrepancies between plasma procalcitonin and C-reactive protein levels are common in acute illness[J]. Acta Paediatr, 2016, 105(5):508-513.
doi: 10.1111/apa.2016.105.issue-5
URL
|
[12] |
Mousa SO, Sayed SZ, Moussa MM, et al. Assessment of platelets morphological changes and serum butyrylcholinesterase activity in children with diabetic ketoacidosis: A case control study[J]. BMC Endocr Disord, 2017, 17(1):23.
doi: 10.1186/s12902-017-0174-6
pmid: 28376867
|
[13] |
Sun Q, Li J, Gao F. New insights into insulin: The anti-inflammatory effect and its clinical relevance[J]. World J Diabetes, 2014, 5(2):89-96.
doi: 10.4239/wjd.v5.i2.89
pmid: 24765237
|
[14] |
Wolfsdorf JI, Nicole G, Mich Ae LA, et al. Diabetic ketoacidosis and hyperglycemic hyperosmolar state: A consensus statement from the International Society for Pediatric And Adolescent Diabetes[J]. Pediatric Diabetes, 2018, 19(Suppl 27):3.
doi: 10.1111/pedi.2018.19.issue-S26
URL
|
[15] |
Schafer AI. Thrombocytosis[J]. N Engl J Med, 2004, 350(12):1211-1219.
doi: 10.1056/NEJMra035363
URL
|
[16] |
Alberio L. Do we need antiplatelet therapy in thrombocytosis? Pro. Diagnostic and pathophysiologic considerations for a treatment choice[J]. Hamostaseologie, 2016, 36(4):227-240.
pmid: 25707870
|
[17] |
Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis[J]. Br J Haematol, 2010, 149(3):352-375.
doi: 10.1111/bjh.2010.149.issue-3
URL
|